Valuations. Apr 2016 ASX listed industrial company Valuation of divisions for purposes of evaluating bids

Transcription

1 2016 Valuations Jan 2016 ASX listed biotech Valuation of options for executive director Feb 2016 ASX listed financial services Valuation of business Feb 2016 ASX listed technology Valuation of director options Mar 2016 Private technology Independent valuation Mar 2016 ASX listed oil and gas Valuation of options for executive director Apr 2016 ASX listed exploration and Valuation of options for directors following a takeover development Apr 2016 ASX listed industrial Valuation of divisions for purposes of evaluating bids Apr 2016 ASX listed exploration Independent valuation for the purposes of s611 item 7 Apr 2016 Oceania Capital Partners Independent valuation for the purposes of s611 item 7, following the Limited share buyback transaction announced by its parent HCI Apr 2016 Private arborist Valuation for the purposes of admitting a new shareholder May 2016 ASX listed personal care Valuations for the purposes of AASB 3 May 2016 Private recruitment firm in the Valuation for the purposes of an acquisition health care space May 2016 ASX listed technology rentals Valuation for the purposes of AASB 3

2 May 2016 ASX listed auto classified Valuation of performance rights business June 2016 ASX mining services Valuation of performance rights June 2016 Privately owned marketing Valuation for the purposes of a group restructure June 2016 Southern Gold Limited Valuation for the purposes of Listing Rule 7.1A.3 July 2016` Law firm Valuation for the purposes of acquiring a partner s interests July 2016 Private 3PL logistics Valuation for the purposes of acquiring a shareholder s interests August 2016 Private individual Expert financial report for purposes of family court litigation valuation of significant holdings in ASX listed companies August 2016 Private Expert financial report for purposes of commercial litigation valuation of brand September 2016 Private gold exploration Valuation of options for the purposes of year end accounts and prospective IPO September 2016 ASX listed biotech Valuation pursuant to s611 item 7, for change of control transaction September 2016 ASX listed biotech Valuation of options for Executive Chairman; reward benchmarking October 2016 ASX listed resources Valuation of options for directors and senior management October 2016 ASX listed medical devices Independent Expert Report, for purposes of a Section 611 item 7 transaction October 2016 ASX listed pharmaceutical Valuation of options for Chief Executive

3 November 2016 Private packaging business Valuation for purposes of capital raising November 2016 November 2016 ASX listed resources ASX listed identity verification Valuation of options and performance rights Valuation of options and performance rights

4 2015 Jan 2015 ASX listed oil and gas explorer Valuation of options for executive director Feb 2015 ASX listed mining exploration Valuation of performance rights for executive director Feb 2015 Private medical clinic Independent valuation Feb 2015 ASX listed biotech Valuation of options for executive director Feb 2015 Law firm Independent valuation for partner dispute Mar 2015 ASX listed mining Valuation of options for senior executives Apr 2015 Private hotel developer Financial model Apr 2015 Apr 2015 Privately owned community assets owner and operator Australian Natural Proteins Limited Financial model Independent valuation for the purposes of seeking shareholder support to an acquisition May 2015 ASX listed mining Valuation of options for director May 2015 Privately owned construction Valuation of shares for the purposes of a share sale transaction May 2015 ASX listed mining Valuation of options for key executive

5 June 2015 Jacana Minerals Limited Independent valuation for the purposes of an Independent Expert Report on the proposed merger with Strandline Resources Limited June 2015 June 2015 ASX listed environmental engineering and services Private hotel development and operating trust Valuation of options for senior executives Financial model July 2015 ASX listed payments Valuation of executive options and performance rights July 2015 July 2015 July 2015 August 2015 August 2015 August 2015 ASX listed gold explorer and producer ASX listed gold explorer, developer and producer ASX listed biopharmaceutical Victorian Government business asset Private water treatment preparing for back door listing ASX listed online classified business Valuation of executive performance rights Valuation of executive options and performance rights Valuation of executive options Valuation for strategic planning purposes Valuation of executive options Valuation of executive performance rights

6 August 2015 ASX listed biotech Valuation of options August 2015 Public unlisted trading exchange preparing for back door listing Report on valuation methodology for restricted employee share issue September 2015 ASX listed biotech Valuation of performance rights September 2015 September 2015 October 2015 October 2015 December 2015 Private with an online booking system ASX listed environmental engineering and services ASX listed medical device ASX listed payments technology ASX listed software development Valuation of share issue Valuation of options and performance rights to be issued to directors and senior executives Valuation of IP Valuation of performance rights and options Valuation of options for executive and non-executive directors

7 2014 Jan 2014 Privately owned medical device Valuation for purposes of a capital raising Mar 2014 Privately owned fund manager Valuation for purposes of share sales Mar 2014 Casino gaming business Valuation and financial modelling for proposed capital raising May 2014 ASX listed environmental services Valuation of executive options May 2014 ASX listed satellite Valuation of performance rights for senior executive Jun 2014 Mid cap ASX listed resources Valuation of assets for the purposes of the directors expressing a view on a proposed corporate transaction Jun 2014 Unlisted public biotech Valuation of director and executive options for accounting purposes Jul 2014 Mid cap ASX listed resources Valuation of director options Aug 2014 ASX listed biotech Valuation of shares for purposes of takeover response strategy Aug 2014 Private Registered Training Organisation Valuation of shares for purposes of sale Aug 2014 Private Education Provider Valuation of business for purposes of sale Sept 2014 ASX listed technology Independent valuation report for the board, for the purposes of a significant restructure to be put to shareholders

8 Sept 2014 ASX listed biotech Valuation of IP for purposes of impairment testing Oct 2014 ASX listed biotech Valuation of performance rights for Directors, for shareholder approval Oct 2014 ASX listed oil and gas Valuation of performance rights for directors, for shareholder approval

9 2013 Feb 2013 Apr 2013 Apr 2013 Early stage medical device Immune System Therapeutics Ltd Australian Natural Proteins Limited Valuation for the purposes of a share incentive award Valuation of director share options Independent Expert Report for section 611 item 7 transaction Apr 2013 Argo Exploration Limited Valuation of performance rights to be granted to the Directors subject to shareholder approval May 2013 Immune System Therapeutics Limited Independent Expert Report for section 611 item 7 transaction Aug 2013 ASX listed biotech Valuation of subsidiary shares for related party transaction Sep 2013 Cellmid Limited Valuation of Advangen Inc. for purposes of ASX Listing Rule 7.1A.3 Sep 2013 Newsat Limited Valuation of directors\' performance rights and options for purposes of a shareholder meeting Oct 2013 HuaYi Resources Limited Valuation of director and broker options for a new IPO on ASX Dec 2013 Invigor Group Limited Independent Expert Report for section 611 item 7 transactions Dec 2013 ASX listed environmental services Valuation of CEO options for accounting purposes

10 Dec 2013 Asset management software Valuation of shares for purposes of a share incentive award

11 2012 Dec 2012 Private pre revenue technology Valuation for purposes of strategic investment Aug 2012 ASX listed healthcare Valuation of consideration options Aug 2012 Jul 2012 Jul 2012 Jul 2012 Jul 2012 Jul 2012 ASX listed base metals and gold exploration and development ASX listed graphite explorer and developer Private consumer network business ASX listed oil and gas exploration and production Public unlisted algae based industrial waste remediation ASX listed environmental products and services ASX listed communications Valuation of director options for purposes of seeking shareholder approval Valuation of remuneration options for financial reporting purposes Valuation for purposes of issuing executive options Valuation of director options for financial reporting purposes Fnancial modelling of project activities Valuation of remuneration options for financial reporting purposes Valuation of executive performance rights

12 Jun 2012 ASX listed healthcare Valuation of healthcare technologies for the purposes of impairment testing May 2012 Public unlisted biotechnology Valuation of director and executive options for financial reporting purposes May 2012 ASX listed resources Independent Expert Report for strategic alliance transaction May 2012 High growth private logistics 3-way forecast financial model for funding purposes May 2012 Private greeting card business Valuation for sale process May 2012 Mar 2012 Private engineering consultancy business Private retail group with diverse interests Valuation for matrimonial settlement 3-way forecast financial model for finance application Mar 2012 ASX listed Anittel Limited Independent Expert Report for section 611(7) transaction Mar 2012 ASX listed healthcare Valuation of early stage technologies for the purposes of impairment testing Mar 2012 NSX listed exploration Valuation of director and executive options for financial reporting purposes Feb 2012 ASX listed oil and gas exploration Start up online technology Valuation of director and executive options for financial reporting purposes Financial modelling for scenario analysis

13 Feb 2012 Private engineering consultancy Independent valuation for purposes of possible sale transaction Jan 2012 ASX listed exploration Valuation of director and executive options for financial reporting purposes Jan 2012 Jan 2012 ASX listed oil and gas exploration Privately owned precious metal trading Valuation of director and executive options and consideration options for financial reporting purposes Independent valuation for purposes of possible sale transaction Jan 2012 National supermarket chain Independent review of financial model for strategic review purposes

14 2011 Dec 2011 ASX listed mining Valuation of director and executive options for financial reporting purposes Dec 2011 Nov 2011 Regional grocery clearance chain Manufacturer and distributer of carbon products Independent valuation Independent valuation for shareholder exit Oct 2011 ASX listed Viento Group Limited Independent Expert Report for section 611 (7) transaction Oct 2011 Private algae Financial modelling updates Jul - Sept 2011 ASX listed CMA Limited Financial modelling for purposes of significant recapitalisation